Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Amneal Pharmaceuticals (AMRX) stock in plain English

Free brief · no signupStart here
AMRXPublished Nov 13, 2026
Amneal Pharmaceuticals Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Develops, manufactures, and sells generic and branded prescription pharmaceuticals across multiple dosage formats.
Assets:
Global manufacturing footprintOperates major pharmaceutical production and packaging plants across the US, India, and Ireland.
Over 7,600 employeesEmploys scientists, technicians, and commercial staff internationally.
Broad commercial portfolioMarkets around 280 generic and specialty products across diverse therapeutic classes.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

46
OPS ScoreOperating finances
Latest quote
-2.24%$21.39
$7.45B
52.5×
$3.20B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was AMRX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Amneal Pharmaceuticals (AMRX) do?

Amneal Pharmaceuticals Inc (AMRX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Develops, manufactures, and sells generic and branded prescription pharmaceuticals across multiple dosage formats. Manufactures complex generic, biosimilar, and specialty drugs across proprietary facilities in the US and India. It is worth $7.45B on the market and sold $3.20B over the last year.

Market cap
$7.45B
P/E ratio
52.5×
Annual sales
$3.20B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 13, 2026

Brands and businesses behind AMRX

  • Rytary: Generates revenue from prescription sales to treat Parkinson disease symptoms in adult patients.
  • Crexont: Earns revenue from prescription sales of extended release carbidopa and levodopa for Parkinson disease management.
  • Unithroid: Generates sales as a daily branded prescription tablet for patients with hypothyroidism.
  • Emverm: Earns revenue from chewable prescription tablets prescribed to treat systemic pinworm and roundworm infections.

AMRX’s flags, in plain English

Each flag is a number from Amneal Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Insiders Hold

Insiders own 55% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Stupid Cash

Can pay this year's bills 1.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Debt Is Driving

Heavy debt, 618% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about AMRX

How big is Amneal Pharmaceuticals?

Amneal Pharmaceuticals’ market cap is $7.45B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.20B: what customers paid the company over the last year, before any costs.

What is AMRX’s P/E ratio?

AMRX’s P/E ratio is 52.5×. Investors pay about 52.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with AMRX?

Heavy debt of over two billion dollars creates substantial interest expense and limits capital allocation flexibility. That is one risk on Amneal Pharmaceuticals’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Amneal Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AMRX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card